There is significant interest in synthesizing large-area graphene films at low temperatures by chemical vapor deposition (CVD) for nanoelectronic and flexible device applications. However, to date, low-temperature CVD methods have suffered from lower surface coverage because micro-sized graphene flakes are produced. Here, we demonstrate a modified CVD technique for the production of large-area, continuous monolayer graphene films from benzene on Cu at 100–300 °C at ambient pressure. In this method, we extended the graphene growth step in the absence of residual oxidizing species by introducing pumping and purging cycles prior to growth. This led to continuous monolayer graphene films with full surface coverage and excellent quality, which were comparable to those achieved with high-temperature CVD; for example, the surface coverage, transmittance, and carrier mobilities of the graphene grown at 300 °C were 100%, 97.6%, and 1,900–2,500 cm2 V−1 s−1, respectively. In addition, the growth temperature was substantially reduced to as low as 100 °C, which is the lowest temperature reported to date for pristine graphene produced by CVD. Our modified CVD method is expected to allow the direct growth of graphene in device manufacturing processes for practical applications while keeping underlying devices intact.
The lateral flow immunosensor (LFI) is a widely used diagnostic tool for biomarker detection; however, its sensitivity is often insufficient for analyzing targets at low concentrations. Here, an electrochemiluminescent LFI (ECL‐LFI) is developed for highly sensitive detection of troponin I (TnI) using Ru(bpy)32+‐loaded mesoporous silica nanoparticles (RMSNs). A large amount of Ru(bpy)32+ is successfully loaded into the mesoporous silica nanoparticles with excellent loading capacity and shows strong ECL signals in reaction to tripropylamine. Antibody‐immobilized RMSNs are applied to detect TnI by fluorescence and ECL analysis after a sandwich immunoassay on the ECL‐LFI strip. The ECL‐LFI enables the highly sensitive detection of TnI‐spiked human serum within 20 min at femtomolar levels (≈0.81 pg mL−1) and with a wide dynamic range (0.001–100 ng mL−1), significantly outperforming conventional fluorescence detection (>3 orders of magnitude). Furthermore, TnI concentrations in 35 clinical serum samples across a low range (0.01–48.31 ng mL−1) are successfully quantified with an excellent linear correlation (R2 = 0.9915) using a clinical immunoassay analyzer. These results demonstrate the efficacy of this system as a high‐performance sensing strategy capable of capitalizing on future point‐of‐care testing markets for biomolecule detection.
A lithographically aligned palladium nano-ribbon (Pd-NRB) array with gaps of less than 40 nm is fabricated on a poly(ethylene terephthalate) substrate using the direct metal transfer method. The 200 μm Pd-NRB hydrogen gas sensor exhibits an unprecedented sensitivity of 10(9) % after bending treatment, along with fast sensing behavior (80% response time of 3.6 s and 80% recovery time of 8.7 s) at room temperature.
The
production of hydrogen peroxide (H2O2) using
photocatalytic nanoparticles is an emerging field with applications
in organic synthesis, biosensors, and fuel cells. Colloidal photocatalysts
are, however, limited in their applications because of poor efficiency
and stability. In this study, millimolar production of H2O2 was achieved within 5 min using solid-phase photocatalystsAu
nanoislands (NIs) on porous TiO2 filmswithout supplying
O2 or stirring the solution. Au/TiO2 showed
an almost 80-fold greater productivity than TiO2, which
can be explained by considering two factors. First, the physical-vapor-deposited
Au resulted in the formation of Au NIs of various sizes on TiO2, whose work functions were size-dependent. Thus, the combination
of small Au NIs, TiO2, and large Au NIs allowed the introduction
of potential gradients through TiO2, and also the reduced potential barriers at the
small Au NI/TiO2 junctions; thereby minimizing the recombination
of electron–hole pairs, and effectively extracting them. Second,
the porous TiO2 films may effectively scatter UV light,
leading to enhanced electron–hole pair generation. The inherent
properties of the solid-phase photocatalysts could also circumvent
stability issues caused by aggregation. These solid-phase photocatalysts
should facilitate the development of high-efficiency H2O2 generation and promote technology based on H2O2-mediated processes.
C-reactive protein (CRP) is used as a general biomarker for inflammation and infection. During stroke and myocardial infarction, CRP increases and is present in a broad concentration range of 1−500 μg/mL. Therefore, full-range CRP detection is crucial to identify patients who need close follow-up or intensive treatment after a heart attack. Here, we report the first attempt to develop an electrochemiluminescent lateral flow immunosensor (ECL-LFI) that allows full-range CRP detection. Ru(bpy) 3 2+ -labeled gold nanoparticles (AuNPs) are used as a CRPtargeting probe and a signal generator; they form sandwich immunocomplexes at the test line of the strip and generate strong ECL emission via a Ru(bpy) 3 2+ /tripropylamine system. The ECL-LFI shows high sensitivity in detecting CRP in spiked serum, with a limit of detection of 4.6 pg/mL within 15 min, and a broad detection range of 0.01−1000 ng/mL, which is 2 orders of magnitude broader than that of conventional colorimetric LFI. The clinical usability of the ECL-LFI was evaluated using 30 clinical serum samples (200 ng/mL to 5 mg/mL), which showed a good linear correlation (R 2 = 0.9896), with a clinical chemistry analyzer. The results suggest that the ECL-LFI holds great potential for CRP detection in point-of-care diagnostics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.